Video Poster Sessions:
2013 EULAR Annual European Congress of Rheumatology
  1. Course List
Chair
faculty image
Leonard H. Calabrese, DO
  • Professor of Medicine
  • Department of Rheumatology and Immunology
  • Cleveland Clinic Lerner College of Medicine
  • Cleveland, Ohio
  • The past few years have seen an explosion in biological therapies effective in treating rheumatoid arthritis. Clinicians are now faced with the task of determining the most beneficial strategies in using these new drugs to define optimal treatment for individual patients. In this selection of reports from EULAR 2013, investigators discuss their most recent clinical trial data, focusing in particular on comparative studies, long-term safety and efficacy, various combination regimens, and when to initiate treatment.
  • Evaluate the benefit of early diagnosis and aggressive intervention in maximizing the achievement of remission, stopping erosion, and avoiding progression in patients with rheumatoid arthritis (RA)
  • Assess efficacy and safety data (including risk of infection, malignancies, and adverse events) of current and emerging biological therapies for RA
  • Identify individual variables/biomarkers that influence treatment selection and monitoring strategies
  • Define the role of immunogenicity and its impact on clinical outcome
  • Target Audience

    This CME/CE activity is designed for rheumatologists, primary care providers (internists and family practice practitioners), nurses/nurse practitioners, pharmacists, physician assistants, and other healthcare providers involved in the management of patients with rheumatoid arthritis (RA).

     

    Activity Goal

    The activity goal is to examine current and emerging strategies for diagnosing, treating, monitoring, and managing patients with rheumatoid arthritis.